New data from clinical practice again confirmed the high efficacy and a favorable safety profile of the drug Xarelto® in patients with atrial fibrillation (Press release of the company Bayer)
.
Saved in:
Main Author: | Article Editorial |
---|---|
Format: | Article |
Language: | English |
Published: |
Столичная издательская компания
2016-09-01
|
Series: | Рациональная фармакотерапия в кардиологии |
Online Access: | https://www.rpcardio.online/jour/article/view/1319 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
NEW DATA OF EXTENSIVE RESEARCH PROGRAM AND THE RESULTS OF STUDIES IN REAL CLINICAL PRACTICE FROM DIFFERENT COUNTRIES REAFFIRMED THE HIGH EFFICACY AND A FAVORABLE SAFETY PROFILE OF RIVAROXABAN (XARELTO®) FROM THE BAYER COMPANY PRESS RELEASE OF THE BAYER COMPANY
by: article editorial
Published: (2017-01-01) -
The Results of Rivaroxaban Studies COMMANDER HF and MARINER Were Published. Bayer Company Press Release .
by: artilce Editorial
Published: (2019-01-01) -
BAYER HEALTHCARE
Published: (2015-04-01) -
Findings Released from NAXOS Analysis. Pfizer Company Press Release
by: article Editorial
Published: (2019-11-01) -
A Simple Extension of Bayer Demosaicing for Lightweight Non-Bayer Demosaicing
by: Ki-Wook Hong, et al.
Published: (2025-01-01)